MX2009010778A - Composiciones y metodos para el tratamiento de insuficiencia cardiaca. - Google Patents

Composiciones y metodos para el tratamiento de insuficiencia cardiaca.

Info

Publication number
MX2009010778A
MX2009010778A MX2009010778A MX2009010778A MX2009010778A MX 2009010778 A MX2009010778 A MX 2009010778A MX 2009010778 A MX2009010778 A MX 2009010778A MX 2009010778 A MX2009010778 A MX 2009010778A MX 2009010778 A MX2009010778 A MX 2009010778A
Authority
MX
Mexico
Prior art keywords
compositions
treatment
methods
heart failure
left ventricular
Prior art date
Application number
MX2009010778A
Other languages
English (en)
Spanish (es)
Inventor
Bruce Edward Markham
Original Assignee
Phrixus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phrixus Pharmaceuticals Inc filed Critical Phrixus Pharmaceuticals Inc
Publication of MX2009010778A publication Critical patent/MX2009010778A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2009010778A 2007-04-05 2008-04-04 Composiciones y metodos para el tratamiento de insuficiencia cardiaca. MX2009010778A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92204707P 2007-04-05 2007-04-05
PCT/US2008/004437 WO2008124088A2 (en) 2007-04-05 2008-04-04 Compositions and methods for the treatment of heart failure

Publications (1)

Publication Number Publication Date
MX2009010778A true MX2009010778A (es) 2010-01-29

Family

ID=39561916

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010778A MX2009010778A (es) 2007-04-05 2008-04-04 Composiciones y metodos para el tratamiento de insuficiencia cardiaca.

Country Status (6)

Country Link
US (2) US8372387B2 (https=)
EP (1) EP2150260A2 (https=)
JP (1) JP2010523569A (https=)
CA (1) CA2682234A1 (https=)
MX (1) MX2009010778A (https=)
WO (1) WO2008124088A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103271935A (zh) 2006-08-01 2013-09-04 普里克萨斯医药股份有限公司 泊洛沙姆用于预防和/或治疗心力衰竭的用途
US8372387B2 (en) 2007-04-05 2013-02-12 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
ES2370205B2 (es) * 2010-05-18 2012-07-04 Universidad De Santiago De Compostela Uso de poloxaminas como inductoras de la diferenciacion osteogenica de celulas mesenquimales
US9579257B2 (en) 2013-08-20 2017-02-28 Anutra Medical, Inc. Haptic feedback and audible output syringe
CA2927361A1 (en) 2013-10-16 2015-04-23 Mast Therapeutics, Inc. Diuretic induced alterations of plasma volume
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
KR102525493B1 (ko) 2014-07-07 2023-04-25 라이프래프트 바이오사이언시즈 인코포레이티드 장기 순환 물질이 없는 폴록사머 조성물 및 이의 제조 방법 및 용도
WO2016007542A1 (en) 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Poloxamer therapy for heart failure
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure
CN112294767A (zh) * 2020-11-17 2021-02-02 海南锦瑞制药有限公司 一种注射用盐酸地尔硫卓冻干粉针剂及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198211A (en) * 1986-05-15 1993-03-30 Emory University Method of treating myocardial damage
ATE187154T1 (de) * 1991-03-19 1999-12-15 Cytrx Corp Polyoxypropylen/polyoxyethylen copolymere mit verbesserter biologischer aktivität
WO1992022202A1 (en) 1991-06-03 1992-12-23 Alpha Therapeutics Corporation Thrombolytic and perfluorochemical treatment for myocardial infraction
US5605687A (en) * 1992-05-15 1997-02-25 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for repair of electrical injury
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
AU1312800A (en) 1998-10-09 2000-05-01 Cytrx Corporation Method and composition for treating ischemia and sickle cell anemia
US6761824B2 (en) * 2000-08-17 2004-07-13 Reeve Lorraine E Process for the fractionation of polymers
CA2426811A1 (en) 2000-10-24 2002-08-29 Smithkline Beecham Corporation Novel formulations of carvedilol
US9557325B2 (en) * 2003-06-09 2017-01-31 Redox-Reactive Reagents Llc Method of altering the binding specificity of proteins by oxidation-reduction reactions
US20050181978A1 (en) * 2003-11-20 2005-08-18 Rasmus Rojkjaer Therapeutic use of factor XI
AU2005289520A1 (en) * 2004-09-27 2006-04-06 Vical Incorporated Formulations and methods for treatment of inflammatory diseases
EP1809272A4 (en) * 2004-10-18 2008-01-02 Maroon Biotech Corp METHOD AND COMPOSITIONS FOR TREATING DAMAGES THROUGH FREE RADICALS
AU2006216420B2 (en) * 2005-02-25 2010-07-15 The Regents Of The University Of Michigan Compositions and methods for treating and preventing cardiomyopathy and heart disease
CN103271935A (zh) * 2006-08-01 2013-09-04 普里克萨斯医药股份有限公司 泊洛沙姆用于预防和/或治疗心力衰竭的用途
US8372387B2 (en) 2007-04-05 2013-02-12 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
WO2009078978A2 (en) 2007-12-14 2009-06-25 Phrixus Pharmaceuticals, Inc. Compositions containing polyglycidol-based polymers and uses thereof
WO2009079562A2 (en) 2007-12-17 2009-06-25 The Regents Of The University Of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies

Also Published As

Publication number Publication date
US8372387B2 (en) 2013-02-12
US20130129662A1 (en) 2013-05-23
WO2008124088A2 (en) 2008-10-16
JP2010523569A (ja) 2010-07-15
WO2008124088A3 (en) 2009-03-12
US20100178269A1 (en) 2010-07-15
EP2150260A2 (en) 2010-02-10
CA2682234A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
MX2009010778A (es) Composiciones y metodos para el tratamiento de insuficiencia cardiaca.
WO2010014690A3 (en) Medical devices for therapeutic agent delivery
WO2010056302A3 (en) Iontophoretic therapeutic agent delivery system
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
WO2008088537A3 (en) Stent with a coating for delivering a therapeutic agent
WO2010090878A3 (en) Apical papillary muscle attachment for left ventricular reduction
EP2671584A3 (en) Compositions and methods for treating disorders associated with salt or fluid retention
WO2018033254A3 (en) Rna for cancer therapy
WO2007128817A3 (en) Insulin derivative
EP3269328A3 (en) Cardiac valve implant
WO2007133520A3 (en) Stent coating comprising titanium oxide or iridium oxide and a therapeutic agent
WO2009034559A3 (en) Cosmetic process for aesthetic and/or repairing treatment of the skin
WO2009026657A8 (en) Flavonoid ppar agonists
WO2012065177A3 (en) Stabilized ablation systems and methods
UA106365C2 (ru) Способ улучшения гликемического контроля и способ снижения жира в организме с применением ингибитора sglt-2
HK1198869A1 (en) Combination treatments for hepatitis c
WO2010149363A3 (en) Pharmaceutical composition comprising rotigotine salts (acid or na), especially for iontophoresis
WO2010009120A8 (en) Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
WO2010071826A3 (en) Methods for treating osteoclast-related disease, compounds and compositions thereof
WO2010091154A3 (en) Compositions and methods for joining non-conjoined lumens
PH12014500274A1 (en) Use of chitosans to increase nail growth rate
WO2011091225A3 (en) Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
MX379191B (es) Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension.
WO2009144551A3 (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood
WO2007130501A3 (en) Combination therapy for treatment of cancer

Legal Events

Date Code Title Description
FG Grant or registration